BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology

Translational Psychiatry

Volumn 7, Issue 8, 2017, Pages

  Wilson, E N ^a,b   Do Carmo, S ^a   Iulita, M F ^a   Hall, H ^a   Ducatenzeiler, A ^a   Marks, A R ^a   Allard, S ^a   Jia, D T ^a   Windheim, J ^a   Cuello, A C ^a  

^a MCGILL UNIVERSITY   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; BETA SECRETASE 1; BETA SECRETASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM DERIVATIVE; NOOTROPIC AGENT; NP 03; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; ASPARTIC PROTEINASE; BACE PROTEIN, RAT; LITHIUM; NEUROPROTECTIVE AGENT; SECRETASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN TISSUE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG FORMULATION; DRUG MICRODOSE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; EXPERIMENTAL AMNESIA; FEMALE; HIPPOCAMPAL TISSUE; HIPPOCAMPUS; MALE; MORRIS WATER MAZE TEST; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PROMOTER REGION; PROTEIN EXPRESSION; RAT; RECTUM MUCOSA; SPATIAL LEARNING; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; MEMORY; MEMORY DISORDER; METABOLISM; PATHOLOGY; TRANSGENIC RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; FEMALE; HIPPOCAMPUS; LITHIUM; MALE; MEMORY; MEMORY DISORDERS; NEUROGENESIS; NEUROPROTECTIVE AGENTS; RATS; RATS, TRANSGENIC;

EID: 85026783851     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2017.169     Document Type: Article

References (75)

1. Kessing LV, Sondergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008; 65: 1331-1335.
2. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Diseasemodifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Bri J Psychiatry 2011; 198: 351-356.
3. Mauer S, Vergne D, Ghaemi SN. Standard and trace-dose lithium: A systematic review of dementia prevention and other behavioral benefits. Aust N Z J Psychiatry 2014; 48: 809-818.
4. Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res 2013; 10: 104-107.
5. Zhang X, Heng X, Li T, Li L, Yang D, Du Y et al. Long-term treatment with lithium alleviates memory deficits and reduces amyloid-beta production in an aged Alzheimer's disease transgenic mouse model. J Alzheimers Dis 2011; 24: 739-749.
6. Nunes MA, Schowe NM, Monteiro-Silva KC, Baraldi-Tornisielo T, Souza SI, Balthazar J et al. Chronic microdose lithium treatment prevented memory loss and neurohistopathological changes in a transgenic mouse model of Alzheimer's disease. PLoS ONE 2015; 10: e0142267.
7. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 2007; 27: 1981-1991.
8. Belmaker RH. Bipolar disorder. N Engl J Med 2004; 351: 476-486.
9. Azab AN, Shnaider A, Osher Y, Wang D, Bersudsky Y, Belmaker RH. Lithium nephrotoxicity. Int J Bipolar Disord 2015; 3: 28.
10. Gelenberg AJ, Jefferson JW. Lithium tremor. J Clin Psychiatry 1995; 56: 283-287.
11. Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, Ehrnhoefer DE et al. NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiol Dis 2012; 48: 282-289.
12. Arribat Y, Talmat-Amar Y, Paucard A, Lesport P, Bonneaud N, Bauer C et al. Systemic delivery of P42 peptide: A new weapon to fight Huntington's disease. Acta Neuropathol Commun 2014; 2: 86.
13. Lehmann S, Relano-Gines A, Resina S, Brillaud E, Casanova D, Vincent C et al. Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorder. PLoS ONE 2014; 9: e88797.
14. Mouri A, Diat O, Lerner DA, El Ghzaoui A, Ajovalasit A, Dorandeu C et al. Water solubilization capacity of pharmaceutical microemulsions based on Peceol(R), lecithin and ethanol. Int J Pharm 2014; 475: 324-334.
15. Mouri A, Diat O, El Ghzaoui A, Bauer C, Maurel JC, Devoisselle JM et al. Phase behavior of reverse microemulsions based on Peceol((R)). J Colloid Interface Sci 2014; 416: 139-146.
16. Mouri A, Legrand P, El Ghzaoui A, Dorandeu C, Maurel JC, Devoisselle JM. Formulation, physicochemical characterization and stability study of lithium-loaded microemulsion system. Int J Pharm 2016; 502: 117-124.
17. Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A et al. A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays preplaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis 2010; 20: 113-126.
18. Qi Y, Klyubin I, Harney SC, Hu N, Cullen WK, Grant MK et al. Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human A-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-A agents. Acta Neuropathol Commun 2014; 2: 175.
19. Iulita MF, Allard S, Richter L, Munter LM, Ducatenzeiler A, Weise C et al. Intracellular Abeta pathology and early cognitive impairments in a transgenic rat model overexpressing human amyloid precursor protein: A multidimensional study. Acta Neuropathol Commun 2014; 2: 61.
20. Galeano P, Martino Adami PV, Do Carmo S, Blanco E, Rotondaro C, Capani F et al. Longitudinal analysis of the behavioral phenotype in a novel transgenic rat model of early stages of Alzheimer's disease. Front Behav Neurosci 2014; 8: 321.
21. Martino Adami PV, Quijano C, Magnani N, Galeano P, Evelson P, Cassina A et al. Synaptosomal bioenergetic defects are associated with cognitive impairment in a transgenic rat model of early Alzheimer's disease. J Cereb Blood Flow Metab 2015; 37: 69-84.
22. Wilson EN, Abela AR, Do Carmo S, Allard S, Marks AR, Welikovitch LA et al. Intraneuronal amyloid beta accumulation disrupts hippocampal CRTC1-dependent gene expression and cognitive function in a rat model of Alzheimer disease. Cereb Cortex 2017; 27: 10.
23. Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 2014; 71: 961-970.
24. Hanzel CE, Pichet-Binette A, Pimentel LS, Iulita MF, Allard S, Ducatenzeiler A et al. Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. Neurobiol Aging 2014; 35: 2249-2262.
25. Morris RGM. Spatial navigation does not require the presence of local cues. Learn Motiv 1981; 12: 236-260.
26. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11: 47-60.
27. Doble BW, Woodgett JR. GSK-3: Tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116(Pt 7): 1175-1186.
28. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004; 29: 95-102.
29. Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A et al. Inhibition of GSK3betamediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest 2013; 123: 224-235.
30. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-789.
31. Wu G, He X. Threonine 41 in beta-catenin serves as a key phosphorylation relay residue in beta-catenin degradation. Biochemistry 2006; 45: 5319-5323.
32. Parr C, Mirzaei N, Christian M, Sastre M. Activation of the Wnt/beta-catenin pathway represses the transcription of the beta-amyloid precursor protein cleaving enzyme (BACE1) via binding of T-cell factor-4 to BACE1 promoter. FASEB J 2015; 29: 623-635.
33. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 1992; 360: 672-674.
34. Das U, Wang L, Ganguly A, Saikia JM, Wagner SL, Koo EH et al. Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway. Nat Neurosci 2015; 19: 55-64.
35. Yan R, Vassar R. Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol 2014; 13: 319-329.
36. Parra-Damas A, Valero J, Chen M, Espana J, Martin E, Ferrer I et al. Crtc1 activates a transcriptional program deregulated at early Alzheimer's disease-related stages. J Neurosci 2014; 34: 5776-5787.
37. Matarin M, Salih DA, Yasvoina M, Cummings DM, Guelfi S, Liu W et al. A genomewide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep 2015; 10: 633-644.
38. Parra-Damas A, Chen M, Enriquez-Barreto L, Ortega L, Acosta S, Perna JC et al. CRTC1 function during memory encoding is disrupted in neurodegeneration. Biol Psychiatry 2016; 81: 111-123.
39. Heinrich A, von der Heyde AS, Boer U, Phu do T, Tzvetkov M, Oetjen E. Lithium enhances CRTC oligomer formation and the interaction between the CREB coactivators CRTC and CBP-implications for CREB-dependent gene transcription. Cell Signal 2013; 25: 113-125.
40. Boer U, Eglins J, Krause D, Schnell S, Schofl C, Knepel W. Enhancement by lithium of cAMP-induced CRE/CREB-directed gene transcription conferred by TORC on the CREB basic leucine zipper domain. Biochem J 2007; 408: 69-77.
41. Heinrich A, Boer U, Tzvetkov M, Oetjen E, Knepel W. Stimulation by lithium of the interaction between the transcription factor CREB and its co-activator TORC. Biosci Rep 2009; 29: 77-87.
42. Zhang C, McNeil E, Dressler L, Siman R. Long-lasting impairment in hippocampal neurogenesis associated with amyloid deposition in a knock-in mouse model of familial Alzheimer's disease. Exp Neurol 2007; 204: 77-87.
43. Haughey NJ, Liu D, Nath A, Borchard AC, Mattson MP. Disruption of neurogenesis in the subventricular zone of adult mice, and in human cortical neuronal precursor cells in culture, by amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. Neuromolecular Med 2002; 1: 125-135.
44. Lie DC, Colamarino SA, Song HJ, Desire L, Mira H, Consiglio A et al. Wnt signalling regulates adult hippocampal neurogenesis. Nature 2005; 437: 1370-1375.
45. Rao MS, Shetty AK. Efficacy of doublecortin as a marker to analyse the absolute number and dendritic growth of newly generated neurons in the adult dentate gyrus. Eur J Neurosci 2004; 19: 234-246.
46. Fiorentini A, Rosi MC, Grossi C, Luccarini I, Casamenti F. Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice. PLoS ONE 2010; 5: e14382.
47. Ch'ng TH, Uzgil B, Lin P, Avliyakulov NK, O'Dell TJ, Martin KC. Activity-dependent transport of the transcriptional coactivator CRTC1 from synapse to nucleus. Cell 2012; 150: 207-221.
48. Sekeres MJ, Mercaldo V, Richards B, Sargin D, Mahadevan V, Woodin MA et al. Increasing CRTC1 function in the dentate gyrus during memory formation or reactivation increases memory strength without compromising memory quality. J Neurosci 2012; 32: 17857-17868.
49. De-Paula VJ, Gattaz WF, Forlenza OV. Long-term lithium treatment increases intracellular and extracellular brain-derived neurotrophic factor (BDNF) in cortical and hippocampal neurons at subtherapeutic concentrations. Bipolar Disord 2016; 18: 692-695.
50. Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A et al. Lithium trial in Alzheimer's disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 2009; 70: 922-931.
51. De Ferrari GV, Inestrosa NC. Wnt signaling function in Alzheimer's disease. Brain Res Brain Res Rev 2000; 33: 1-12.
52. Anderton BH, Dayanandan R, Killick R, Lovestone S. Does dysregulation of the Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer's disease Mol Med Today 2000; 6: 54-59.
53. De Ferrari GV, Avila ME, Medina MA, Perez-Palma E, Bustos BI, Alarcon MA. Wnt/ beta-catenin signaling in Alzheimer's disease. CNS Neurol Disord Drug Targets 2014; 13: 745-754.
54. Inestrosa NC, Varela-Nallar L. Wnt signaling in the nervous system and in Alzheimer's disease. J Mol Cell Biol 2014; 6: 64-74.
55. Toledo EM, Inestrosa NC. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry 2010; 15: 272-285, 228.
56. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668.
57. Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VM, Klein PS. Activation of the Wnt signaling pathway: A molecular mechanism for lithium action. Dev Biol 1997; 185: 82-91.
58. Ferretti MT, Allard S, Partridge V, Ducatenzeiler A, Cuello AC. Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. J Neuroinflammation 2012; 9: 62.
59. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci 2011; 34: 185-204.
60. Do Carmo S, Hanzel CE, Jacobs ML, Machnes Z, Iulita MF, Yang J et al. Rescue of early bace-1 and global DNA demethylation by S-adenosylmethionine reduces amyloid pathology and improves cognition in an Alzheimer's model. Sci Rep 2016; 6: 34051.
61. Tapia-Rojas C, Burgos PV, Inestrosa NC. Inhibition of Wnt signaling induces amyloidogenic processing of amyloid precursor protein and the production and aggregation of Amyloid-beta (Abeta)42 peptides. J Neurochem 2016; 139: 1175-1191.
62. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860-866.
63. Llorens-Martin M, Jurado J, Hernandez F, Avila J. GSK-3, a pivotal kinase in Alzheimer disease. Front Mol Neurosci 2014; 7: 46.
64. Aimone JB, Deng W, Gage FH. Resolving new memories: A critical look at the dentate gyrus, adult neurogenesis, and pattern separation. Neuron 2011; 70: 589-596.
65. Sahay A, Wilson DA, Hen R. Pattern separation: A common function for new neurons in hippocampus and olfactory bulb. Neuron 2011; 70: 582-588.
66. Drew LJ, Kheirbek MA, Luna VM, Denny CA, Cloidt MA, Wu MV et al. Activation of local inhibitory circuits in the dentate gyrus by adult-born neurons. Hippocampus 2015; 26: 763-778.
67. Akers KG, Martinez-Canabal A, Restivo L, Yiu AP, De Cristofaro A, Hsiang HL et al. Hippocampal neurogenesis regulates forgetting during adulthood and infancy. Science 2014; 344: 598-602.
68. Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry 2008; 23: 704-711.
69. Morris G, Berk M. The putative use of lithium in Alzheimer's disease. Curr Alzheimer Res 2016; 13: 853-861.
70. Iulita MF, Ower A, Barone C, Pentz R, Gubert P, Romano C et al. An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: relation to cognitive decline and longitudinal evaluation. Alzheimers Dement 2016; 12: 1132-1148.
71. Severus WE, Kleindienst N, Seemuller F, Frangou S, Moller HJ, Greil W. What is the optimal serum lithium level in the long-term treatment of bipolar disorder-a review Bipolar Disord 2008; 10: 231-237.
72. Leyhe T, Eschweiler GW, Stransky E, Gasser T, Annas P, Basun H et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis 2009; 16: 649-656.
73. Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement 2016; 12: 195-202.
74. Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT et al. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated beta-amyloid. Alzheimers Dement 2016; 12: 195-202.
75. Epelbaum S, Genthon R, Cavedo E, Habert MO, Lamari F, Gagliardi G et al. Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. Alzheimers Dement 2017; 13: 454-467.